3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Neuroblastoma
2
Lymphoma
2
Skin Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metabolic Diseases
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunologic Deficiency Syndromes
1
Hepatoblastoma
1
Ganglioneuroblastoma
1
Anemia, Aplastic
1
Interventions
Pemetrexed
4
Cisplatin
4
pembrolizumab
3
Nivolumab
3
Interleukin-2
3
Carboplatin
3
atezolizumab
2
aldesleukin
2
Pharmaceutical Preparations
2
Ipilimumab
2
olaparib
1
lenvatinib
1
fludarabine
1
enzalutamide
1
Thoracoscopy
1
Thoracic Surgery, Video-Assisted
1
Surgery, Computer-Assisted
1
Proton Therapy
1
Platinum
1
Paclitaxel
1
Injections
1
Influenza Vaccines
1
Indocyanine Green
1
In Situ Hybridization, Fluorescence
1
Cyclophosphamide
1
Combined Modality Therapy
1
Cerebral Decortication
1
Brentuximab Vedotin
1
Blood Component Removal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Mesothelioma, Malignant
×
Influenza Vaccines
×
Clear all
NCT07510815
2026-04-06
DUAL-MESO-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled